102 related articles for article (PubMed ID: 35039230)
21. Commentary on "Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?" Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108-13 [Epub 2012 Aug 15].
See WA
Urol Oncol; 2013 Jul; 31(5):716-7. PubMed ID: 23796200
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel in the treatment of advanced urothelial cancer.
Bajorin DF
Oncology (Williston Park); 2000 Jan; 14(1):43-52, 57; discussion 58, 61-2. PubMed ID: 10680149
[TBL] [Abstract][Full Text] [Related]
23. Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC).
Bloudek L; Wright P; McKay C; Derleth CL; Lill JS; Lenero E; Hepp Z; Ramsey SD; Sullivan SD; Devine B
Curr Oncol; 2023 Mar; 30(4):3637-3647. PubMed ID: 37185390
[TBL] [Abstract][Full Text] [Related]
24. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Griesinger F; Korol EE; Kayaniyil S; Varol N; Ebner T; Goring SM
Lung Cancer; 2019 Sep; 135():196-204. PubMed ID: 31446995
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
Vander Velde N; Guerin A; Ionescu-Ittu R; Shi S; Wu EQ; Lin SW; Hsu LI; Saum KU; de Ducla S; Wang J; Li S; Thåström A; Liu S; Shi L; Leppert JT
Eur Urol Oncol; 2019 Feb; 2(1):12-20. PubMed ID: 30929841
[TBL] [Abstract][Full Text] [Related]
27. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.
Huang SY; Wu CC; Hsieh MC; Rau KM; Chiang PH; Sung MT; Luo HL; Huang CC; Huang CH; Liu JM; Su HY
Oncology; 2020; 98(3):146-153. PubMed ID: 31794969
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
[TBL] [Abstract][Full Text] [Related]
30. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
Wei XX; Werner L; Teo MY; Rosenberg JE; Koshkin VS; Grivas P; Szabados B; Morrison L; Powles T; Carril-Ajuria L; Castellano D; Velho PI; Hahn NM; McKay RR; Raggi D; Necchi A; Kanesvaran R; Alerasool P; Gaines J; Galsky M; Bellmunt J; Sonpavde G
J Urol; 2021 Feb; 205(2):414-419. PubMed ID: 32935617
[TBL] [Abstract][Full Text] [Related]
31. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
32. Systemic chemotherapy for advanced bladder cancer: update and controversies.
Garcia JA; Dreicer R
J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
[TBL] [Abstract][Full Text] [Related]
34. Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma.
Graf RP; Fisher V; Huang RSP; Hamdani O; Gjoerup OV; Stanke J; Creeden J; Levy MA; Oxnard GR; Gupta S
JCO Precis Oncol; 2022 Aug; 6():e2200121. PubMed ID: 35977348
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and carboplatin in bladder cancer: recent developments.
Vaughn DJ
Eur J Cancer; 2000 Jul; 36 Suppl 2():7-12. PubMed ID: 10908842
[TBL] [Abstract][Full Text] [Related]
36. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.
Leow JJ; Martin-Doyle W; Fay AP; Choueiri TK; Chang SL; Bellmunt J
Eur Urol; 2014 Sep; 66(3):529-41. PubMed ID: 24680361
[TBL] [Abstract][Full Text] [Related]
37. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Rajeswaran A; Trojan A; Burnand B; Giannelli M
Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy with methotrexate, carboplatin, mitoxantrone (Novantrone) and vincristine (Oncovin) in transitional-cell urothelial cancer.
Pectasides D; Mylonakis A; Antoniou F; Kostopoulou M; Triantaphyllis D; Papadopoulou M; Varthalitis J; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(2):139-44. PubMed ID: 9499188
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
Ardizzoni A; Boni L; Tiseo M; Fossella FV; Schiller JH; Paesmans M; Radosavljevic D; Paccagnella A; Zatloukal P; Mazzanti P; Bisset D; Rosell R;
J Natl Cancer Inst; 2007 Jun; 99(11):847-57. PubMed ID: 17551145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
